Silymarin reduces retinal microvascular damage in streptozotocin-induced diabetic rats.

Karimi, Rahman; Bakhshi, Ali; Dayati, Parisa; Abazari, Omid; Shahidi, Maryamsadat; Savaee, Mohamadreza; Kafi, Ehsan; Rahmanian, Mehdi; Naghib, Seyed Morteza

Diabetic retinopathy is a severe microvascular problem in diabetes mellitus. Silymarin is a flavonoid compound, and according to previous studies, it is a bioactive compound with potent antioxidant and anti-inflammatory properties. This investigation aims to peruse the impact of silymarin against diabetic retinopathy in streptozotocin (STZ)-provoked rats. Thirty-two adult male Wistar rats were randomly allocated into the control group, STZ group, STZ silymarin (50 mg/kg), and STZ silymarin (100 mg/kg). STZ rats received silymarin every day until 2 months after diabetes induction. The serum and retinal tissues were collected 2 months after silymarin treatment to determine biochemical and molecular analyses. Silymarin markedly lowered the serum glucose concentration in diabetic rats. Silymarin reduced the increased levels of advanced glycosylated end products (AGEs), the receptors for AGEs (RAGE), and reactive oxygen species (ROS) in diabetic rats. Silymarin also attenuated the phosphorylation of p38 MAP kinase and nuclear factor (NF)-κB p65 and diminished diabetes-induced overexpression of inflammatory cytokines, vascular endothelial growth factor (VEGF), adhesion molecules, and extracellular matrix proteins in STZ rats. Our data suggested that silymarin has protective effects against diabetic retinopathy, which might be related to the inhibition of the AGEs/RAGE axis and its antioxidant and anti-inflammatory activities.

SILYMARIN; STREPTOZOTOCIN; VASCULAR endothelial growth factors; RECEPTOR for advanced glycation end products (RAGE); LABORATORY rats; GLYCOSYLATED hemoglobin; FLAVONOIDS; EXTRACELLULAR matrix proteins

Scientific Reports, 2022, Vol 12, Issue 1, p1

2045-2322

Academic Journal

10.1038/s41598-022-20297-2